the aid library

LIST OPTIONS

Filter

8518

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Malawi

Africa Center for Disease Control and Prevention (2023) CC

The Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) project has conducted a multi-year, multi-country study that provides stark insights on the under-reported depth of the antimicrobial resistance (AMR) crisis across Africa and lays out urgent policy recommendations to addr... more

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Nigeria

Africa Center for Disease Control and Prevention (2023) CC

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Senegal

Africa Center for Disease Control and Prevention (2023) CC

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Tanzania

Africa Center for Disease Control and Prevention (2023) CC

External Link

Mapping Antimicrobial Resistance and Antimicrobial Use Partnership (MAAP) Country Report Uganda

Africa Center for Disease Control and Prevention (2023) CC

Download (289)

View PDF (385)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

National User Guide on the Prevention and Treatment of Hypertension in Adults at the PHC Level 2021

Health Department: Republic of South Africa (2021) CC

Hypertension is referred to as a “silent killer”. Most people with hypertension are unaware of their condition as in most cases, they experience no warning signs or symptoms hence they are not identified or treated. Hypertention is associated with a number of conditions, disability, and causes o... more

External Link

IRC Ethiopia strategic plan 2022-2025

Internationam Water and Sanitation Centre (2023) CC

After introducing Ethiopia's WASH sector challenges and trends, the plan describes IRC Ethiopia's vision and strategy which draws from IRC and Water For People's joint framework - Destination 2030. It then details the organisational changes and business development needed to implement the strategic ... more

Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study

Rosengren, A.; Smyth, A.; Rangarajan, S. et al. The Lancet Global Health (2019) CC

Socioeconomic status is associated with differences in risk factors for cardiovascular disease incidence and outcomes, including mortality. However, it is unclear whether the associations between cardiovascular disease and common measures of socioeconomic status—wealth and education—differ among... more

National Essential Medicines List - Tertiary/Quaternary Medication Review Process

Republic of South Africa (2017) CC

Long Acting Muscarinic Antagonists (LAMA) such as tiotropium and glycopyrronium are used in the management of COPD1. They have been shown to improve lung function, quality of life and exercise tolerance. They have also been associated with reduced COPD-related exacerbations, associated hospitalisati... more

The availability, prices and affordability of essential medicines in Malawi: A cross-sectional study

Khuluza, F.; Haefele-Abah, C. PLoS ONE (2019) CC

The Malawian government recently introduced cost-covering consultation fees for self-referral patients in tertiary public hospitals. Previously, patients received medicines free of charge in government-owned health facilities, but must pay elsewhere. Before the government implements a payment policy... more

Barriers to childhood asthma care in sub-Saharan Africa: a multicountry qualitative study with children and their caregivers

Naidoo, K.L.; Dladla, S.; Mphahlele, R.E. et al. BMJ Open (2023) CC

This study identifies barriers and provides recommendations to improve asthma care in children across sub-Saharan Africa, where qualitative data is lacking despite high rates.

A summary of the new GINA strategy: a roadmap to asthma control

Reddel, H. K.; Bateman, E. D.; Becker, A.; et al. (2015) CC2

Over the past 20 years, the Global Initiative for Asthma (GINA) has regularly published and annually updated a global strategy for asthma management and prevention that has formed the basis for many national guidelines. However, uptake of existing guidelines is poor. A major revision of the GINA r... more

Health emergency preparedness for imported cases of high-consequence infectious diseases

European Centre for Disease Prevention and Control (ecdc) (2022) C_CDC

Preparedness planning is essential in order to respond effectively to outbreaks, including single case occurrences of highconsequence infectious diseases (HCID), such as the importation of a viral haemorrhagic fever (VHF) case

Sexual and reproductive health and rights infographic snapshot

World Health Organization WHO (2021) C_WHO

This country snapshot provides an overview of national data relating to sexual and reproductive health and rights (SRHR) throughout the life course. Realization of SRHR requires provision of comprehensive, people-centred services, that address the different elements of SRHR, and which are supported ... more

The Malawi Noncommunicable Diseases & Injuries Poverty Commission Report

Republic of Malawi; Ministry of Health (2018) CC2

As our world changes, so too does the burden of disease. Globalisation, evolving trade and consumption patterns, and increased access to life-saving medical care are just some of the factors that have transformed the global health landscape.

How immunization strengthens the fight against antimicrobial resistance

World Health Organization WHO (2024) C_WHO

Vaccines contribute to the battle against antimicrobial resistance (AMR) by preventing infections and thereby reducing antimicrobial use and the incidence of disease from resistant pathogens. By preventing infection transmission, vaccines extend population protection by also reducing the risk of inf... more

Download (81179)

View PDF (1067)

Adolescent Sexual and Reproductive Health Toolkit for Humanitarian Settings (arabic)

UNFPA, Save the Children USA (2009)

This Toolkit is intended to guide humanitarian programme managers and healthcare providers to ensure that sexual and reproductive health interventions put into place both during and after a crisis are responsive to the unique needs of adolescents.

External Link

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module
recommended

Krause, S.; S. Chynoweth, D. Quick et al. Women's Refugee Commission, IAWG (2019) C1

The module is currently available in English, French, Nepali, Portuguese, Russian, and Spanish

Download (986)

View PDF (1580)

Managing Incomplete Abortion

WHO, International Cooperation of Midwifes WHO (2008)

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module recommended

Minimum Initial Service Package (MISP) for Reproductive Health in Crisis Situations: a Distance Learning Module
recommended